---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-028684"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T09:55:04.283684+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Elite Pharma Q1 revenue up 17% to $9.0M; net income up 267% to $1.1M

## Summary
- Revenue $9.0M (+16.9% YoY); operating profit $1.6M (+60% YoY).
- Net income attributable to common shareholders $1.1M (+267% YoY).
- Growth driven by launch of Elite Laboratories label product line.

## SEC filing metadata
- accession: 0001493152-23-028684
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315223028684/0001493152-23-028684-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315223028684/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-028684
- JSON: https://secwatch.observer/filing/0001493152-23-028684.json
- Plain text: https://secwatch.observer/filing/0001493152-23-028684.txt

## Key facts
- Earnings Releases
  ELITE PHARMACEUTICALS INC /NV/ reported first quarter of fiscal year 2024 ended June 30, 2023 results: revenue $9.0 million, net income $1.1 million.
  - Period: first quarter of fiscal year 2024 ended June 30, 2023
  - Revenue: $9.0 million
  - Net income: $1.1 million
  - Result: reported results
  source text: Consolidated revenues for the three-month period ended June 30, 2023, were $9.0 million, an increase of $1.3 million or 16.9% as compared to the comparable period of the prior fiscal year. Operating profits were $1.6 million, an increase of $0.6 million or 60% from the comparable period of the prior year. Net income attributable to common shareholders was $1.1 million, an increase of $0.8 million or 267% from the comparable period of the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053369/000149315223028684/0001493152-23-028684-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.